84 evidence-first reviews in this topic, built on 489 peer-reviewed citations. Null and negative trials are reported alongside the positive ones — that is the point of the format.
What the evidence actually shows about resveratrol's healthspan potential, from bone density to knee pain.
Where the evidence lands: Resveratrol shows specific benefits for bone density in postmenopausal women and mixed evidence for knee osteoarthritis, but its role as a broad longevity compound is limited with modest effects.
The evidence for acetyl-L-carnitine is limited to specific conditions, with no direct support for lifespan extension.
Where the evidence lands: Acetyl-L-carnitine (ALCAR) shows some evidence for specific benefits in diabetic neuropathy, prefrailty, and dementia, but it is not supported as a general longevity or healthspan enhancer.
What the evidence actually shows about this popular supplement.
Where the evidence lands: Ubiquinol shows specific benefits for endothelial function in heart failure and migraine prevention, but evidence for broad longevity claims is lacking.
A July 2026 Nature Reviews Genetics review from the lab that discovered fisetin's senolytic activity says the field still cannot reliably tell a senescent cell from another cell fate. The…
Where the evidence lands: Senolytics rest on strong mouse data and a short list of small human trials that almost all used prescription dasatinib alongside quercetin. The largest randomised test in ordinary ageing people missed its primary endpoint, benefit appeared only in an exploratory subgroup defined by a research-only assay, and fisetin's human evidence is mostly absorption studies. There is still no validated way to measure your own senescent cell burden.
Ranked by the strength of human evidence for an outcome that matters, not by mechanism. Creatine, protein, HMB and a daily multivitamin have randomized trials with functional endpoints.…
Where the evidence lands: Nothing in this evidence base tested human lifespan; every result below is a proxy. The best-supported compounds are cheap and pair with resistance training: creatine added 1.37 kg of lean tissue across 22 RCTs and 721 older adults; HMB added 4.61 kg of grip strength and 0.11 m/s of gait speed over 12 weeks in 34 sarcopenic adults; whey improved gait speed and muscle mass in 1,154 sarcopenic patients, though a stricter synthesis found the grip gain (+2.31 kg) below the minimally important difference. A daily multivitamin improved memory in COSMOS-Web (3,562 adults) by the equivalent of 3.1 years of age-related memory change, but in COSMOS-Mind it did not lower incident MCI or dementia. Large trials were null for hard endpoints: VITAL found HRs of 0.96 (cancer) and 0.97 (CVD) for vitamin D and 0.92 (CVD) for omega-3; DO-HEALTH found nothing across six primary endpoints in 2,157 adults. Urolithin A, NMN, spermidine, fisetin and taurine have biomarker data, exploratory signals, or null primary endpoints only. Beta-carotene raised all-cause mortality (RR 1.10) in the 884-trial micronutrient synthesis.
Oral NMN and nicotinamide riboside reliably raise blood NAD+ — nicotinamide riboside by 22% to 142% depending on dose. Across randomized trials, grip strength, gait speed, insulin…
Where the evidence lands: NAD precursors do the biochemical thing they claim. Nicotinamide riboside raised whole blood NAD+ by 22%, 51% and 142% at 100, 300 and 1000 mg/day over eight weeks; NMN raised blood NAD significantly at 300, 600 and 900 mg/day over 60 days in 80 adults; pharmaceutical NMN moved NAD+ from 16.0 to 42.6 µg/mL in 14 days. Clinical outcomes are another matter. A 2025 meta-analysis found no NMN effect on skeletal muscle index (MD −0.42, p=0.14), gait speed (MD −0.01, p=0.79) or chair-stand time. NR did not improve clamp-measured insulin sensitivity in 40 obese men, or cognition in two MCI trials that doubled or 2.6-folded blood NAD+. Raising NAD+ nearly threefold in 42 hospitalised COVID-19 patients left creatinine, CRP, IL-6 and TNFα unchanged. Positives exist — sleep quality and four-metre walk time as secondary endpoints in a trial whose primary was null, LDL and diastolic blood pressure in a 30-person 28-day study. Doses studied: 250 mg–2 g/day NMN, 1000–3000 mg/day NR. No trial has compared NMN with NR head-to-head, and no outcomes trial of IV NAD+ for anti-aging or wellness indications exists.
It is manufactured by an organ, carried on a binding protein, activated in two hydroxylation steps and read by a nuclear receptor — and the trials behave exactly as that biology predicts.
Where the evidence lands: Vitamin D is a secosteroid hormone that was named as a vitamin in the era when it was found in cod liver oil. Because it runs on a feedback loop rather than a supply curve, repletion is where the benefit lives: the two largest trials were null on their primary endpoints in already-replete populations, and an annual 500,000 IU bolus increased falls and fractures instead of reducing them.
A landmark three-year trial preserved knee joint space while the larger NIH GAIT trial found glucosamine no better than placebo — and the much-shared mortality association is…
Where the evidence lands: For knee osteoarthritis the trial record is genuinely split and guidelines disagree; the lifespan signal (hazard ratio 0.85) is association, not causation.
The giant COSMOS trial gave cocoa flavanols the fairest test any supplement has had. The headline outcome was null; the secondary results were intriguing; the honest reading is 'component…
Where the evidence lands: In the COSMOS randomized trial, daily cocoa extract did not significantly reduce total cardiovascular events, though cardiovascular death was 27% lower in secondary analyses; smaller trials show modest vascular benefits (+1.2 points of flow-mediated dilation, ~2 mmHg blood pressure), and cognition and diabetes-prevention outcomes were null.
Green tea catechins produce small but measurable metabolic effects in pooled randomized trials, and habitual tea drinking tracks with lower mortality in huge cohorts. Concentrated…
Where the evidence lands: Expect modesty: pooled trials show green tea catechins yield on the order of 1 kg of weight loss and small improvements in cholesterol, blood pressure and glucose — often judged not clinically meaningful — while observational links to 9–13% lower mortality cannot prove cause, and EGCG intakes at or above about 800 mg/day carry a flagged liver-injury risk.
Marine omega-3s reliably lower triglycerides and modestly lower blood pressure — and yet the giant cardiovascular trials disagree with each other in instructive ways, including one where…
Where the evidence lands: EPA/DHA supplements reliably reduce triglycerides (roughly 15% at higher doses), and high-dose purified EPA cut ischemic events by 25% in statin-treated patients with elevated triglycerides — but 1 g/day blends did little in primary prevention, Cochrane found little or no mortality benefit, and doses above 1 g/day raise atrial fibrillation risk.
Beta-alanine reliably raises muscle carnosine and produces a small but statistically real ergogenic effect for high-intensity efforts of roughly one to four minutes; benefits for strength,…
Where the evidence lands: A safe, modest tool for the one-to-four-minute burn zone of high-intensity exercise; the broader strength and anti-aging claims outrun the evidence.
Randomized trials and meta-analyses support alpha-lipoic acid for relieving diabetic-neuropathy symptoms, with 600 mg/day the identified optimal dose — but the four-year NATHAN 1 trial…
Where the evidence lands: ALA is among the better-evidenced supplements for neuropathy symptom relief; disease modification remains unproven, one long trial was null, and a rare autoimmune-hypoglycemia flag exists.
A striking result from one tiny overnight experiment is being sold as a universal brain boost. A newer replication makes the real story more useful—and more modest.
Where the evidence lands: A single high dose of creatine improved one language-processing measure by 29.1% in a 15-person sleep-deprivation experiment, but that was a pooled baseline-adjusted contrast—not a universal boost in thinking. A 29-person replication found smaller 6–12% signals, mostly below its multiple-testing threshold; normal daily cognition and longevity benefits remain unproven.
Broccoli-sprout sulforaphane flips one of biology's master antioxidant switches. Human trials show modest blood-glucose and detoxification effects — biomarker-level wins, not…
Where the evidence lands: Concentrated broccoli-sprout sulforaphane modestly lowers fasting glucose and HbA1c in dysregulated type 2 diabetes and subsets of prediabetes (about 0.2 mmol/L average in a 2025 trial, larger in predicted responders), and enhances carcinogen detoxification — but benefits are biomarker-level, and bioavailability depends on active myrosinase.
Blood ergothioneine falls with age, and low levels track with cognitive decline, cardiovascular disease, frailty, and mortality in observational cohorts — but the human data are almost…
Where the evidence lands: A genuinely intriguing 'longevity vitamin' candidate with striking cohort associations and one small positive pilot trial — but the human benefits remain suggestive rather than established.
Inulin reliably feeds beneficial gut bacteria, eases constipation and nudges metabolic markers in prediabetes and type 2 diabetes — but the average effects are small, the certainty is…
Where the evidence lands: Inulin is a genuinely functional prebiotic fiber — good for stool frequency, gut bacteria and modest glycemic and lipid improvements in the right populations — but it is not a proven treatment or longevity intervention, and bloating is a common, honest trade-off.
Probiotics have genuine randomized-trial support for a handful of specific problems — antibiotic-associated C. difficile diarrhea above all — and a long tail of modest, strain-dependent…
Where the evidence lands: Probiotics are best understood as strain-specific tools: a Cochrane review of 31 trials found they cut the risk of C. difficile-associated diarrhea during antibiotic use from 4.0% to 1.5%, while benefits elsewhere are modest and a head-to-head review found multi-strain blends are not inherently superior to single strains.
Low-dose lithium orotate sits in a peculiar evidence gap: prescription lithium prevents suicide in mood disorders, trace lithium in drinking water correlates with less dementia, and a…
Where the evidence lands: The defensible position: lithium is a biologically active element with striking observational and animal signals at low doses, one proven benefit at prescription doses in psychiatric illness, and zero completed randomized trials of supplement-level lithium orotate for cognition, mood, or aging.
Boswellia serrata extracts reduce osteoarthritis pain and stiffness in multiple randomized trials and meta-analyses, sometimes within days — but many studies are small, industry-sponsored…
Where the evidence lands: Boswellia extract is a plausibly effective, short-term-safe option for osteoarthritis symptoms — with real mechanistic backing — but trial quality issues and poor absorption of boswellic acids mean the specific extract matters and certainty remains limited.
IV NAD sells immediacy; NR and NMN pills have more human data. Both can move biomarkers, but neither has proved longer life.
Where the evidence lands: Oral NR and NMN consistently raise NAD-related biomarkers and occasionally produce population-specific functional signals; direct IV NAD has mainly pharmacokinetic and tolerability data. No route has proved broad rejuvenation or longer human life, and IV delivery adds procedural and product-quality risks.
Oral NMN reliably raises NAD+ in human blood — on that, the trials agree. Whether that rise buys anything a person would notice is, after dozens of small studies, still unresolved.
Where the evidence lands: NMN demonstrably raises blood NAD+ and is generally well tolerated at studied doses, but functional benefits are modest and inconsistent, and no trial has measured lifespan or disease prevention.
Quercetin shows a small blood-pressure effect at higher doses in meta-analyses of randomized trials — but almost everything else claimed for it, including its famous senolytic story, is…
Where the evidence lands: The strongest human evidence is a modest ~2–3 mmHg blood-pressure reduction, mainly at ≥500 mg/day in people with hypertension; the senolytic fame comes from the dasatinib-plus-quercetin drug pairing, not over-the-counter quercetin.
A single organ-support gummy packs lutein, zeaxanthin, nattokinase, inulin, apple cider vinegar, rutin and trehalose. The evidence behind those seven compounds ranges from large randomized…
Where the evidence lands: The ingredients in multi-organ formulas carry wildly uneven human evidence — strongest for lutein and zeaxanthin, weakest for rutin and trehalose — and no trial has tested the combination, so any benefit is an inference, not a finding.
MSM is one of the most-discussed joint supplements on the internet; its human trials are small, short, often industry-funded, and report modest knee pain and quality-of-life benefits of…
Where the evidence lands: Small randomized trials suggest MSM modestly improves knee pain and knee-related quality of life, mostly at 2–6 g/day, and it appears well tolerated up to about 4–6 g/day; the effects are small, some trials found nothing, and a 1,500 mg product sits at the low end of studied doses.
Akkermansia muciniphila improved insulin sensitivity, insulinemia and cholesterol in a landmark human trial — but a larger 2026 multicenter trial missed its primary endpoint, benefits may…
Where the evidence lands: Akkermansia supplementation is safe and metabolically promising in small human trials — especially the pasteurized form — but the largest trial to date was negative overall, so this remains an early-stage, subgroup-dependent intervention, not a proven one.
Meta-analyses of randomized trials find oral PEA reduces chronic pain of mixed origin and is well tolerated — but heterogeneity is very high, study quality is often low, publication bias…
Where the evidence lands: PEA is a promising, well-tolerated adjunct for chronic pain that often takes one to two months to show benefit; it is not a proven stand-alone therapy, and its anti-aging angle remains preclinical.
Urolithin A — a metabolite some gut microbiomes make from pomegranate ellagitannins — stimulates mitophagy and improved muscle strength and endurance in randomized trials of middle-aged…
Where the evidence lands: The defensible claim is narrow: ellagitannin-derived urolithin A modestly improved muscle function in small human trials, pomegranate products modestly lowered blood pressure in meta-analyses, and your own microbiome decides whether the fruit's compounds ever become that molecule.
Apigenin inhibits CD38, the enzyme that drains NAD+ as tissues age — a beautiful mechanism demonstrated in animals and cells. In humans, the molecule has never been tested at supplement…
Where the evidence lands: Apigenin is a pharmacological CD38 inhibitor that raises NAD+ in animal and cell studies, but human evidence comes only from chamomile extracts (which deliver far less apigenin) — whether capsules raise NAD+ or affect aging in people is unproven.
Luteolin reliably calms inflammatory signaling in rodent brains and cultured cells, and small human trials — mostly of luteolin combined with other agents — report intriguing benefits. But…
Where the evidence lands: The defensible bottom line: luteolin has a consistent anti-neuroinflammatory mechanism in preclinical models and promising, indication-specific human signals — most notably for smell recovery after COVID-19 in combination with palmitoylethanolamide — but standalone luteolin failed its placebo-controlled test and remains unproven for human cognitive aging.
L-methylfolate is the already-active form of folate, and trials show it raises folate status and lowers homocysteine at least as well as folic acid — with its best-tested use as an…
Where the evidence lands: L-methylfolate reliably improves folate status and lowers homocysteine, and at 15 mg/day it improved response in SSRI-resistant depression (NNT around 6) — but hard outcomes are mixed, the 7.5 mg dose failed, and longevity uses are extrapolation, not evidence.
Glucosamine and chondroitin are among the most studied joint supplements on earth — and after decades of trials, the honest summary is a draw: possibly useful for some knees, dismissed by…
Where the evidence lands: For painful knee osteoarthritis, the glucosamine–chondroitin combination performed no better than placebo overall in the landmark GAIT trial but matched celecoxib in the MOVES trial; meta-analyses and guidelines remain genuinely split.
Phosphatidylcholine is a structural brick of every cell membrane and the diet's main form of choline — yet its clinical record is a stack of contradictions: a colitis program that soared…
Where the evidence lands: Delayed-release phosphatidylcholine genuinely helped ulcerative colitis patients in randomized trials and a meta-analysis — until two large phase 3 trials failed in 2024 — while the liver, brain, and anti-aging claims rest on small studies, null results, or mechanistic work, not on proven human benefit.
Betaine (trimethylglycine) reliably lowers the amino acid homocysteine in human blood — a real, dose-dependent, well-replicated effect on a lab number. Whether lowering that number…
Where the evidence lands: Oral betaine lowers fasting and post-load homocysteine in a dose-dependent way (about 1.2 µmol/L on average at 4 g/day and above) and a prescription form is FDA-approved for homocystinuria — but homocysteine lowering has never been shown to reduce cardiovascular events, and doses around 4 g/day modestly raise total cholesterol.
Magnesium genuinely lowers blood pressure by a couple of points in pooled trials and shows modest sleep benefits in the sleepless — but most of the research used other salt forms, so the…
Where the evidence lands: Oral magnesium lowers blood pressure about 2 mmHg on average and can modestly improve insomnia, especially in people with low intake — but benefits are small, absent in the already-healthy, and mostly not specific to the glycinate form.
Acetyl-L-carnitine shuttles fat into the cellular furnace and crosses into the brain — and for depression, fatigue in the very old, and maybe diabetic nerve pain, the human trials are…
Where the evidence lands: ALCAR has modest but real trial support for depressive symptoms in older adults, fatigue in the very old, and possibly diabetic neuropathy — but a Cochrane review found no clear cognitive benefit in healthy people, and large modern trials are still missing.
Resveratrol became famous as the red-wine compound that extended lifespan in laboratory organisms. Two decades into human testing, the picture is quieter: modest vascular and…
Where the evidence lands: In people with metabolic or cardiovascular risk, resveratrol at 500 mg/day or more modestly improves endothelial function and inflammation markers — but it has never been shown to prevent heart attacks, dementia, or early death, and its celebrated longevity mechanism remains preclinical.
CoQ10's best human evidence is as an adjunct in chronic heart failure — striking relative-risk reductions still graded low certainty — while migraine prevention has real support and the…
Where the evidence lands: CoQ10 is a promising but low-certainty adjunct in heart failure and has genuine support for migraine prevention; no trial shows it extends life in healthy people, and the statin muscle-pain rationale failed testing.
Creatine monohydrate plus resistance training reliably adds modest lean mass and strength, including in older adults, and modestly improves memory — but the bone benefits are unproven and…
Where the evidence lands: At 3–5 g/day, creatine is among the best-evidenced and best-tolerated supplements for strength and lean mass when paired with resistance training; claims beyond that — bone density, big cognitive effects, benefits without exercise — are weak, inconsistent, or absent.
Behind every beetroot shot is a person watching a blood-pressure reading edge upward with age. The nitrate science is real — about 5 mmHg on average — and the limits are real too.
Where the evidence lands: Beetroot juice and dietary nitrate modestly lower systolic blood pressure (about 5 mmHg on average in hypertension trials) and improve some exercise-capacity measures, but trials are small and short, and no study has tested stroke or heart-attack outcomes.
Grape seed extract pools to a systolic blood-pressure reduction of roughly 2–6 mmHg across meta-analyses — larger in younger, obese, or metabolic-syndrome patients — with inconsistent…
Where the evidence lands: Grape seed extract has a coherent mechanism and a small, real blood-pressure effect in pooled trials — and nothing yet on heart attacks, strokes, or lifespan.
Pycnogenol improves endothelial surrogate markers and trims about 3 mmHg off blood pressure in pooled trials, but a Cochrane review grades nearly all of its outcomes very low certainty,…
Where the evidence lands: Pycnogenol shows mechanistically plausible, small vascular effects on surrogate measures; the certainty is graded at the bottom of the scale and no clinical-outcome trial exists.
Citrus hesperidin improves endothelial function and inflammatory markers in small human trials and trims cholesterol and blood pressure modestly — inconsistently, with variable…
Where the evidence lands: Hesperidin shows suggestive surrogate improvements — better endothelial function, small LDL and TNF-alpha reductions — but pressure effects are inconsistent and no trial has tested heart attacks, strokes, or death.
Astaxanthin, the carotenoid that colors salmon, reliably shifts oxidative-stress biomarkers in human trials — lowering malondialdehyde, raising antioxidant capacity — but no large trial…
Where the evidence lands: Astaxanthin is biologically active as an antioxidant in humans, with modest signals for skin moisture, fatigue, and some joint and inflammatory outcomes; anti-aging claims beyond biomarkers and skin are extrapolations, not findings.
In small randomized trials, saffron extract at roughly 20–30 mg/day reduces mild-to-moderate depressive symptoms and performs comparably to SSRIs with fewer adverse events, and modestly…
Where the evidence lands: Saffron is among the better-supported botanicals for mild mood and sleep complaints, yet the evidence base is small, short-term, partly industry-funded, and not a substitute for prescribed treatment.
L-carnitine ferries fat into mitochondria, and the heart runs on that ferry. Older trials suggest it helps after a heart attack — fewer deaths, less arrhythmia, smaller infarcts — but the…
Where the evidence lands: Meta-analyses of older, mostly small trials associate L-carnitine given around acute myocardial infarction with reduced mortality and ventricular arrhythmias, and a centenarian trial found less fatigue at 2 g/day — but large modern trials are absent, and gut-bacterial conversion to TMAO is a genuine unresolved safety question for everyday supplementation.
Glycine is a building block for collagen, glutathione, creatine and heme, and small trials show 3 grams before bed improves subjective sleep — but the studies are tiny, some are…
Where the evidence lands: About 3 g of glycine at bedtime improves subjective sleep quality in small trials, and glycine-plus-cysteine combinations show intriguing aging-related effects — but the human evidence is early, small-scale and largely unreplicated.
PQQ is a redox-active compound from soil and natto that grows mitochondria in rodent and cell studies — and a handful of small, short, mostly Japanese and manufacturer-linked human trials…
Where the evidence lands: Small human trials of PQQ (roughly 20 mg/day, up to 12 weeks, a few dozen participants) report improved memory, attention, and cognitive flexibility, with one trial raising BDNF and cerebral oxygen saturation — but the celebrated mitochondrial-biogenesis mechanism is cell-and-rodent work, and no large independent human trial or hard clinical endpoint exists.
Observational cohorts tie polyphenol-rich diets to lower mortality, and randomized trials show modest improvements in blood pressure, lipids and glucose — but the big supplement trials…
Where the evidence lands: The strongest evidence favors varied, polyphenol-rich dietary patterns; supplement trials show modest metabolic effects and some nulls, so a mixed polyphenol blend is an inference from the diet literature, not a tested product.
Myo-inositol, a precursor of insulin's second messengers, improved insulin sensitivity and ovulation in PCOS trials and roughly halved gestational-diabetes risk in a low-certainty Cochrane…
Where the evidence lands: For PCOS and gestational-diabetes risk, myo-inositol has real but mixed randomized-trial support and a benign safety profile; it is not proven superior to metformin, and for aging or longevity it is essentially unstudied.
Randomized trials and meta-analyses find MSM produces statistically significant but generally small reductions in joint pain — slower and weaker than NSAIDs, with inconsistent results,…
Where the evidence lands: The fair label claim is 'supports joint comfort': MSM is well tolerated and shows small benefits in some trials, but nothing in the human literature shows it rebuilds cartilage or modifies joint disease.
Lutein and zeaxanthin failed the headline test in the landmark AREDS2 trial, then a decade of follow-up showed they slow progression of macular degeneration and safely replaced a risky…
Where the evidence lands: For people who already have age-related macular degeneration, lutein plus zeaxanthin is among the best-supported supplements in existence — it slows progression to late disease over ten years and safely replaces beta-carotene. It does not prevent the disease in healthy eyes, and the cognition claims are narrow and mixed.
For the person staring at the ceiling at three in the morning, tart cherry extract offers a gentle, food-level hope. Small trials say it may add sleep; better-powered trials say maybe not.…
Where the evidence lands: Small randomized and crossover trials show tart cherry modestly increases sleep time and quality (over an hour of extra objectively measured sleep in one pilot), but recent better-powered trials were null — at best a mild, food-level sleep aid, not a treatment for insomnia.
All-in-one longevity formulas bundle a dozen compounds aimed at the hallmarks of aging. The strongest evidence belongs to individual ingredients — often at doses, and in combinations, that…
Where the evidence lands: No controlled human trial has tested the finished multi-ingredient formula; the evidence is ingredient-level, mostly early-stage, and frequently involves doses far above what a daily sachet delivers.
Carnosine — the muscle dipeptide that buffers acid and traps glycation chemistry — modestly lowered fasting glucose and HbA1c in meta-analyses of randomized trials in prediabetes and type…
Where the evidence lands: Across meta-analyses, carnosine or beta-alanine supplementation modestly improves glycemic markers in people with prediabetes or type 2 diabetes; the trials are small and short, several outcomes were null, and nothing yet shows it changes long-term health outcomes.
Glucosamine and chondroitin — the backbone of Osteo Bi-Flex — have been tested in some of the largest supplement trials ever run. The verdict is genuinely split: a landmark NIH trial found…
Where the evidence lands: For painful knee osteoarthritis, glucosamine plus chondroitin is safe and may modestly ease symptoms — one trial found the combination comparable to celecoxib in severe pain — but the pivotal GAIT trial found no clinically meaningful benefit overall, and the lifespan claims rest on observational data with a documented selection-bias problem.
Milk thistle's extract, silymarin, is the world's default herbal answer to a frightening diagnosis: fatty liver. Meta-analyses show it modestly improves liver enzymes and metabolic markers…
Where the evidence lands: Silymarin modestly lowers ALT and AST and improves cholesterol, triglycerides and fasting insulin in pooled NAFLD trials — but a rigorous biopsy-based NASH trial missed its primary endpoint (with only a fibrosis signal: 22.4% vs 6.0% over placebo), a landmark cirrhosis trial found no survival benefit, and nothing shows it prevents cirrhosis or liver-related death.
Standardized olive leaf extract shows modest, repeatable blood-pressure reductions in people with prehypertension and hypertension, plus small lipid effects — but trials are small,…
Where the evidence lands: Olive leaf extract's best human evidence is a modest blood-pressure-lowering effect in people with elevated readings, with small cholesterol and triglyceride improvements and two positive knee-pain trials — real but adjunctive-scale effects, limited by small samples and inconsistent extract quality.
Zinc anchors supplement stacks and cold-season rituals alike. The trial record says: a modest, contested shortening of colds, a real role in one landmark eye trial, and no proof for…
Where the evidence lands: Oral zinc started soon after symptom onset can modestly shorten colds (with low-certainty evidence), and high-dose zinc helped slow macular degeneration progression in the AREDS trial — but prevention is unproven and chronic high doses carry a copper-deficiency risk.
Vinegar can blunt some post-meal glucose responses, but the weight-loss evidence is small, heterogeneous, and weakened by a prominent retraction.
Where the evidence lands: The best-supported vinegar effect is a modest change in some post-meal glucose responses. Durable weight loss and disease prevention remain unproven, especially after a prominent weight-loss paper was retracted.
DHEA levels decline with age, but randomized reviews do not show broad restoration of strength, cognition, function, or lifespan from supplementation.
Where the evidence lands: An age-related fall in DHEA does not prove a deficiency syndrome. Trials show limited, outcome-specific effects rather than whole-body rejuvenation or longer life.
Linoleic acid is often described online as inflammatory or toxic. Controlled feeding trials and clinical outcome data do not support that blanket claim.
Where the evidence lands: Mechanistic concerns about omega-6 fats do not translate into evidence that ordinary seed-oil intake causes systemic inflammation. Food quality, cooking, dose, and what the oil replaces matter more than the viral label.
A small 2009 rugby study raised DHT concerns without measuring hair. A 2025 randomized trial measured follicles directly and found no significant difference.
Where the evidence lands: The hair-loss claim was inferred from DHT, not observed hair loss. A direct 2025 randomized trial found no significant follicular harm, although very long-term effects cannot be ruled out completely.
A large UK Biobank study linked glucosamine use with lower mortality. A later methods paper showed how selection alone could create nearly the same effect.
Where the evidence lands: Glucosamine use is associated with lower mortality in large cohorts, but prevalent-user and healthy-participant selection can reproduce an effect of similar size. Randomized glucosamine trials address osteoarthritis symptoms, not lifespan.
Molecular hydrogen has plausible signaling effects and small metabolic trials. The evidence does not show detoxification, disease prevention, or longer life.
Where the evidence lands: Small trials suggest possible biomarker effects from measured hydrogen exposure, but no clinical evidence establishes disease prevention or longevity. Consumer products may not reproduce studied doses.
One human infusion pilot mapped metabolism during a six-hour drip. It did not show better energy, cognition, addiction recovery, or slower aging.
Where the evidence lands: A small infusion study showed that IV NAD+ is extensively metabolized. It did not prove better energy, cognition, recovery, or slower aging, and controlled efficacy trials are still missing.
Several pilot trials report cognitive signals, but samples are small, products differ, follow-up is short, and dementia prevention has not been shown.
Where the evidence lands: Small trials provide preliminary cognitive signals for some lion’s mane preparations. They do not establish brain regeneration or dementia prevention, and product standardization remains a major gap.
Animal work suggests brain penetration, but human cognition trials are small, often use combination formulas, and do not establish dementia prevention.
Where the evidence lands: Rodent brain-magnesium findings are not proof of human cognitive rejuvenation. Small and often multi-ingredient trials are interesting, but larger independent studies are needed.
Melatonin can help selected sleep and circadian problems, but high-dose longevity claims rely heavily on mechanisms and animal research rather than human outcomes.
Where the evidence lands: Melatonin has indication-specific sleep evidence, not human longevity evidence. High-dose anti-aging claims extrapolate from mechanisms and animal work, while long-term safety remains incompletely defined.
Correcting deficiency and taking high-dose vitamin D are different interventions. Large trials have not shown broad cancer or cardiovascular prevention, and bolus dosing can increase falls.
Where the evidence lands: Treating vitamin D deficiency is not the same as using high doses for longevity. Large randomized trials are neutral for major prevention outcomes, and bolus dosing has increased falls in older adults.
COSMOS found modest cognitive benefits in older adults, while three large cohorts found no mortality advantage. Neither result makes a multivitamin a substitute for diet or care.
Where the evidence lands: COSMOS supports a modest average cognitive benefit in older adults, while large cohorts show no mortality advantage. A multivitamin may fill gaps but is not a proven dementia-prevention or longevity treatment.
A plant alkaloid with real metabolic effects, an AMPK mechanism, and a marketing problem.
Where the evidence lands: Berberine has credible AMPK-driven effects on blood sugar and cholesterol in randomized trials of varying quality, but it is not a weight-loss drug and carries real GI side effects and CYP/P-gp drug interactions.
One of the most studied supplements helps preserve muscle and may aid memory in older adults, but the muscle benefit depends largely on pairing it with resistance exercise.
Where the evidence lands: Creatine monohydrate is safe and reliably boosts muscle and strength gains in older adults when paired with resistance training, with modest emerging benefits for memory but little effect on bone.
Small trials reported sweeping benefits; a larger independent trial missed its main glutathione target.
Where the evidence lands: GlyNAC rests on a plausible glutathione-restoration idea and looks safe, but the sweeping benefits come from very small single-group trials, while the largest independent trial missed its primary glutathione endpoint except in a low-baseline subgroup.
Both raise blood NAD+ in randomized trials, but the clinical payoff remains modest and unproven, and one of them sits in regulatory limbo in the US.
Where the evidence lands: NMN and NR both dependably raise blood NAD+ in randomized human trials, but proven health benefits in people remain modest and unsettled.
Fish-oil fats nudged biological-aging clocks in one trial, but the heart-disease record is genuinely mixed.
Where the evidence lands: Omega-3 slightly slowed biological-aging clocks in one trial, but its effect on actual heart-disease outcomes ranges from clear (high-dose EPA in high-risk patients) to nonexistent (general prevention), so it is promising, not proven.
Broccoli-sprout sulforaphane switches on the cell's antioxidant defense system, but the human trials range from encouraging to flatly null.
Where the evidence lands: Sulforaphane convincingly switches on the Nrf2 detox pathway, but human outcomes are mixed, some trials are null, and absorption depends heavily on preparation.
A 2023 Science paper showed taurine extends healthy lifespan in mice and monkeys, but the human evidence is still observational, not causal.
Where the evidence lands: Taurine extended healthy lifespan in mice and monkeys and declines with age in humans, but the human data are only correlational, so its anti-aging benefit in people remains unproven pending clinical trials.
A gut-derived metabolite that switches on mitochondrial cleanup has real human data, including trials that missed their main goals.
Where the evidence lands: Urolithin A reliably shifts mitochondrial biomarkers and appears safe, but two of its randomized trials missed their primary strength and walking-distance endpoints, so functional benefits remain unproven.
Evidence suggests spermidine may support healthy aging, but human data is still emerging.
Where the evidence lands: Spermidine shows promise for longevity based on lab and animal studies, with preliminary human evidence suggesting possible benefits, but more research is needed to confirm effects.
A look at the research behind NMN supplementation for healthspan and longevity.
Where the evidence lands: The available evidence suggests NMN supplementation can increase NAD⁺ levels and may offer some benefits for certain aspects of healthspan, but more research is needed to confirm its effects on longevity.
Fisetin, a flavonol, shows promise as a senolytic agent, but human longevity benefits remain to be demonstrated.
Where the evidence lands: Fisetin shows early promise as a senolytic in lab studies, but human longevity benefits remain unproven—more research is needed.
A critical look at the evidence behind Magellan NAD⁺ Activation Capsules.
Where the evidence lands: Magellan NAD⁺ Activation Capsules combine ingredients with some promising but preliminary evidence in animals and limited human data; realistic expectations should be cautious until more robust clinical trials are available.
Learn what the evidence says about key ingredients in this all-in-one longevity formulation.
Where the evidence lands: The ingredients in NOVOS Core have shown promise in laboratory studies for supporting pathways linked to aging, but human data on lifespan or healthspan extension is limited.
395 distinct peer-reviewed papers, published 1995–2026, across 238 journals. Each links to its PubMed record; where Magellan has published a full study write-up, that is linked too.
Moderate evidence
In human health, the best-supported effects of resveratrol come from randomized trials and…
Moderate evidence
Randomized trials and meta-analyses report modest benefits on cognition in mild cognitive…
Moderate evidence
In human trials CoQ10 has been studied mainly as an adjunct in cardiovascular disease: the…
Moderate evidence
In randomized trials and their meta-analyses in type 2 diabetes, berberine has produced…
Strong evidence
Across meta-analyses and randomized trials, creatine monohydrate combined with resistance training…
Moderate evidence
Randomized trials show that oral glutathione supplementation can genuinely raise body stores — a…
Moderate evidence
In randomized controlled trials, NMN reliably increases blood NAD+ levels and has generally been…
Moderate evidence
Across large randomized trials and meta-analyses, marine omega-3s reliably reduce serum…
Moderate evidence
Human trials indicate that concentrated broccoli-sprout sulforaphane can modestly lower fasting…
Moderate evidence
A landmark 2023 study reported that taurine declines with age in mice, monkeys, and humans and…
Moderate evidence
In human research, urolithin A supplementation is safe and bioavailable and improves markers of…
Moderate evidence
In model organisms (yeast, worms, flies and mice) spermidine induces autophagy and extends…
Emerging evidence
Because senescent cells accumulate with age and contribute to frailty, vascular dysfunction,…
Emerging evidence
Several of NOVOS Core's ingredients have genuine, though mostly early-stage, human or animal…
Prefer the interactive version? Open the article feed in the Magellan app →